Using AI to predict risks in endometrial cancer management

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify new risk factors for endometrial cancer by employing an integrated multi-omics approach linked to a specific immune pattern known as the MOMIMIC score. It focuses on predicting the progression from precancerous lesions to endometrial carcinoma, assessing prognosis and recurrence risks to aid clinical decision-making. The study utilizes artificial intelligence algorithms to enhance the precision of hysteroscopic procedures and improve the characterization of patients' prognoses. By modulating surgical approaches based on risk profiles, the study seeks to preserve fertility in young patients with low-risk profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years;
* Histological diagnosis of endometrial hyperplasia, endometrioid adenocarcinoma of the endometrium, healthy endometrium in patients undergoing total hysterectomy for benign extra-endometrial disease;
* Written informed consent (to the study and data processing), for the party's patients only prospective and/or in follow-up) For the retrospective cohort: availability of samples adequately stored at the biobank of the Institute and availability of data relating to follow-up (at least 2 years)

Exclusion Criteria:

All exclusion criteria adopted in the surgical protocols will be applied to the study. In particular:

* Comorbidities not controlled with adequate medical therapy;
* Infections of the endometrial cavity (pyometra);
* Synchronous cancer;
* Neoadjuvant treatments;
* Previous radiotherapy treatments of the pelvic region;
* Hormone therapies.

Where it's running

• IRCCS National Cancer Institute "Regina Elena"
  Rome, Italy Recruiting

Study contacts

• Study coordinator: Enrico Vizza, Doctor
• Email: enrico.vizza@ifo.it
• Phone: 06 52666974

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• National registry of endometrial cancer cases in Italy

  This project will collect clinical and molecular information from adults treated for endometrial cancer at participating Italian oncology centers to see if a national database can improve understanding of outcomes and care.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07558889

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Diet approaches to help overweight women with endometrial cancer preserve fertility and lose weight

  This study will see if intermittent fasting or a low-energy balanced diet help overweight or obese women with endometrial cancer lose weight and improve metabolic and tumor-related outcomes while they undergo fertility-preserving treatment.

  Recruiting Peking University People's Hospital · Beijing · NCT07318727

• Weight management for overweight endometrial cancer patients undergoing fertility-sparing treatment

  This study tests if a weight management program can help overweight women with endometrial cancer who want to preserve their fertility feel better and improve their treatment results.

  Recruiting Peking University People's Hospital · Beijing, China · NCT06169449

• Testing VLS-1488 for advanced cancers

  This study is testing a new oral medication called VLS-1488 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 13 sites Phase 1/2 Volastra Therapeutics, Inc. · Los Angeles, California and 13 other locations · NCT05902988

• Pembrolizumab plus Ataluren for metastatic colorectal or endometrial cancer with mismatch repair changes

  This trial will try the combination of pembrolizumab and ataluren in adults with metastatic colorectal cancer (with or without mismatch repair deficiency) or metastatic mismatch-repair-deficient endometrial cancer to see if the treatment is safe and helps shrink tumors.

  Recruiting Phase 1/2 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT04014530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.